Mabtas RA 500mg (Rituximab)

Contact us for more information
Wishlist Compare
Brand nameMabtas RAInternational trade nameRituxanActive substanceRituximabStrength500mg/50mlCategoryAnti Cancer

Description  of  Mabtas RA 500mg (Rituximab 500mg)

Mabtas RA 500mg (Rituximab 500mg) is an anticancer medicine which prevents the growth and spread of cancer cells in the body.
Mabtas RA 500mg (Rituximab 500mg) will help to prevent the Non- Hodgkin’s lymphoma or chronic lymphocytic and with combination with another anticancer drug like methotrexate is used for rheumatoid arthritis symptoms in adult treatment.
Mabtas RA 500mg (Rituximab 500mg) with steroid regimen combination is given for the treatment of some rare disorders which cause blood vessels and other tissues inflammation in the body.

INDICATIONS of  Mabtas RA 500mg (Rituximab 500mg)

Mabtas RA 500mg (Rituximab 500mg) and hyaluronidase human injection are given alone or combination with otherdrugs to treat certain types of non-Hodgkin's lymphoma and chronic lymphocytic leukemia (cancer start in WBC).
Mabtas RA 500mg (Rituximab 500mg) injection combination with methotrexate (Otrexup, Rasuvo, Xatmep, others) is also indicated for the treatment rheumatoid arthritis symptoms in adults that have been already treated with a some type of regimen knowns as tumor necrosis factor (TNF) inhibitor. Mabtas RA 500mg (Rituximab 500mg) is a type in a classification of drugs called monoclonal antibodies.
Mabtas RA 500mg (Rituximab 500mg) is used to killing cancer cells to treat NHL , CLL, rheumatoid arthritis, granulomatosis with polyangiitis, and microscopic polyangiitis by inhibiting the activity of the immune system parts that can injury the joints, veins, and other blood vessels and cause organs (heart and lungs) damage.

MECHANISM OF ACTION  of  Mabtas RA 500mg (Rituximab 500mg)

Mabtas RA 500mg (Rituximab 500mg) is a type of class called as monoclonal antibody. A new type of "targeted" cancer treatment and an integral part of the body's immune system. Naturally the body fused to antibodies in along with an antigen which has entered the body and attack the antigen for destruction by the immune system.
Monoclonal antibiotics which only targeted by an essential cell only, they may cause less toxicity to healthy cell and it is prescribed treatment given only for cancers in which antigens (and the respective antibodies) have been already identified.
Mabtas RAinjection works by linking to the CD20 antigen on normal and malignant B-cells. Hence natural immune security of body are initiated to attach and kill the marked B-cells. Young cells (stem cells) in the bone marrow which will develop into the various cell types and do not have the CD20 antigen. After treatment CD20 antigen allows healthy B-cells to multiply.

Absorption of  Mabtas RA 500mg (Rituximab 500mg)

Not available

Distribution of  Mabtas RA 500mg (Rituximab 500mg)

volume of distribution is 3.1 L.There are no human plasma level

Metabolism of  Mabtas RA 500mg (Rituximab 500mg)

Mabtas RA 500mg (Rituximab 500mg) metabolized by human antimurine antibody production .

Excretion of  Mabtas RA 500mg (Rituximab 500mg)

Mabtas RA 500mg (Rituximab 500mg) metabolized by human antimurine antibody production

 SIDE EFFECTS  of  Mabtas RA 500mg (Rituximab 500mg)

Common effects: fever and chills (flu lik symptoms)
Less common side effects:
Weakness; nausea ; headache; cough ; dyspnea ; pharyngitis


PRECAUTIONS  of  Mabtas RA 500mg (Rituximab 500mg)

Allgeric condition against Mabtas RA 500mg (Rituximab 500mg) or any other medication inform your doctor. Information about past medical history used which include in prescription, non-prescription, vitamins &supplements , nutritional products just inform the doctor. While using Mabtas RA 500mg (Rituximab 500mg) do not take any vaccination or immunization without taking advice from doctors. Avoid use of Mabtas RA 500mg (Rituximab 500mg) if you are pregnant. It will harm the baby unborn, while using Mabtas RA 500mg (Rituximab 500mg) use correct birth control to prevent pregnancy and for at least 2 weeks after your treatment ends. Mabtas RA 500mg (Rituximab 500mg) may affect the ability to have children in women. Inform your doctor if you planning to pregnant. It is unknown whether Mabtas RA 500mg (Rituximab 500mg) passes into breast milk , avoid breast-feed while on Mabtas RA 500mg (Rituximab 500mg) treatment.


DRUG INTERACTION of  Mabtas RA 500mg (Rituximab 500mg)

Mabtas RA 500mg (Rituximab 500mg) drug interaction has limited data is available at present. Interation with fludarabine or cyclophosphamide have no effects in pharmacokinetics in CLL patients.Ikgdar combination with methotrexate had no effects in pharmacokinetics

OVERDOSAGE of Mabtas RA 500mg (Rituximab 500mg)

If over dose occurs seek immediately to the emergency department or poison control help line.
please consult the doctor for further clarification.

CONTRAINDICATION of Mabtas RA 500mg (Rituximab 500mg)

Hypersensitivity or murine proteins. Active severe infectons in rheumatoid arthritis Uncontrolled cardiac disease.

PREGNANCY  of Mabtas RA 500mg (Rituximab 500mg)

Category C : In animal studies reproduction describes an adverse effect on the fetus. There is no adequate and well developed studies in humans, using in pregnant women benefits by warrant use of the drug.

LACTATION  of Mabtas RA 500mg (Rituximab 500mg)

The drug excretion into human milk is unknown. Because the drug is a higher protein molecule and has no information is available. Women should not breast feed during Mabtas RA 500mg (Rituximab 500mg) treatment and till12 months following last dose.

DOSAGE of  Mabtas RA 500mg (Rituximab 500mg)

Mabtas RA 500mg (Rituximab 500mg) injection is usually used to administrate only via intravenous infusion not by IV push or bolus.
First infusion: Starting treatment rate of 50 mg/hr is administer , in not showing infusion toxicity, rate raised up to 50 mg/hr increments at intervals of 30 min and max of 400 mg/hr. Successive infusion: initial at rate of 100 mg/hr, in not showing infusion toxicity, rate raised upto 100 mg/hr increments at intervals of 30 min and max of 400 mg/hr. While combination with CHOP chemotherapy the injection Mabtas RA 500mg (Rituximab 500mg) has not been given. Hence Premedication with corticosteroids must be considered.
The drug Dose is 375 mg/m2 as an IV infusion. Once weeks for 4 or 8 doses administrated for Relapsed treatment Once weekly for 4 doses administrated for Retreatment for relapsed. Previously untreated: administer on day 1 of each cycle of chemotherapy, up to 8 doses. In complete or partial response of patient, start with 8 weeks for maintenance following Mabtas RA 500mg (Rituximab 500mg) in combination with chemotherapy completed then administer 8weeks for 12 doses as a single agent. Once weekly for 4 doses at intervals of 6 months and max of 16 dose for Non – progression (following CVP chemotherapy completion 6 – 8 cycles): On day 1 each cycle of chemotherapy up to 8 infusions for Diffuse large B- cell NHL
Before starting of FC chemotherapy, dose recommended is 375 mg/m2 followed 500 mg/m2 on day 1 of 2-6 cycles every 28 days.

STORAGE  of  Mabtas RA 500mg (Rituximab 500mg)

Store the drug at 2℃ – 3℃ Keep away from the childerns Use the drug before expiry date Protected from direct sunlight and Do not freeze or shake. Discard the unused drug by asking the advice from doctor or pharmacist.

MISSED DOSE of  Mabtas RA 500mg (Rituximab 500mg)

If a dose missed then have the drug soon you remembered, if next dose time reach then leave the missed dose and follow the normal schedule. Do not have 2 dose at a same time. Please consult with doctor for further details.

Brand name:
Mabtas RA
International trade name:
Active substance:
Anti Cancer
Intas Pharma
1 Vial
Product form:

No reviews found

Write feedback
Worldwide delivery

Our company ships from India to all countries of the world.

Genuine and Authentic products

All products supplied from the manufacturer of WHO : GMP certified facilities and ISO Certified facilitates

Economical and Affordable prices

All the products are supplying from manufacturing companies of India